BDBM224288 5-(6-(5-chloropyridin-3-yl)-7-(1- ((trans)-4-methylcyclohexyl)ethyl)- 8-((r)-3-phenylmorpholino)-7h- purin-2-yl)-1,3,4-oxadiazol-2(3h)- one::US9540377, 18.14
SMILES: CC([C@H]1CC[C@H](C)CC1)n1c(nc2nc(nc(-c3cncc(Cl)c3)c12)-c1n[nH]c(=O)o1)N1CCOC[C@H]1c1ccccc1
InChI Key:
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
p53-binding protein Mdm2 (Homo sapiens (Human)) | BDBM224288 (5-(6-(5-chloropyridin-3-yl)-7-(1- ((trans)-4-methy...) | PDB GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.620 | n/a | n/a | n/a | n/a | n/a | 25 |
Merck Sharp & Dohme Corp. US Patent | Assay Description An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re... | US Patent US9540377 (2017) BindingDB Entry DOI: 10.7270/Q2RF5X1F | |||||||||||
More data for this Ligand-Target Pair |